Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Covington
Novartis
Merck
Fuji
Baxter
Teva
Argus Health
US Army
Farmers Insurance

Generated: February 25, 2018

DrugPatentWatch Database Preview

Mylan Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for MYLAN PHARMS INC, and when can generic versions of MYLAN PHARMS INC drugs launch?

MYLAN PHARMS INC has two hundred and forty approved drugs.

There are eleven US patents protecting MYLAN PHARMS INC drugs. There are twenty-nine tentative approvals on MYLAN PHARMS INC drugs.

There are one hundred and ninety-one patent family members on MYLAN PHARMS INC drugs in thirty-nine countries and three hundred and eighty-six supplementary protection certificates in thirteen countries.

Summary for Mylan Pharms Inc
International Patents:191
US Patents:11
Tradenames:196
Ingredients:186
NDAs:240

Drugs and US Patents for Mylan Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc PAROXETINE HYDROCHLORIDE paroxetine hydrochloride TABLET;ORAL 075716-003 Mar 8, 2004 DISCN No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc PERPHENAZINE perphenazine TABLET;ORAL 206691-004 Apr 14, 2017 AB RX No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc METOPROLOL SUCCINATE metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 202033-001 Dec 15, 2011 AB RX No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc ESCITALOPRAM OXALATE escitalopram oxalate CAPSULE;ORAL 077660-002 Jul 31, 2007 DISCN No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc EXEMESTANE exemestane TABLET;ORAL 203315-001 Mar 10, 2017 AB RX No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc TEMOZOLOMIDE temozolomide CAPSULE;ORAL 205227-006 Jun 29, 2016 AB RX No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc METOPROLOL SUCCINATE metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 202033-003 Dec 15, 2011 AB RX No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc DIDANOSINE didanosine CAPSULE, DELAYED REL PELLETS;ORAL 090788-001 Apr 8, 2010 DISCN No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc OLUX E clobetasol propionate AEROSOL, FOAM;TOPICAL 022013-001 Jan 12, 2007 AB2 RX Yes Yes 8,962,000 ➤ Sign Up Y ➤ Sign Up
Mylan Pharms Inc FAMOTIDINE famotidine TABLET;ORAL 075457-002 Apr 18, 2001 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Mylan Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Pharms Inc LUXIQ betamethasone valerate AEROSOL, FOAM;TOPICAL 020934-001 Feb 28, 1999 6,126,920 ➤ Sign Up
Mylan Pharms Inc ZOVIRAX acyclovir CAPSULE;ORAL 018828-001 Jan 25, 1985 4,199,574 ➤ Sign Up
Mylan Pharms Inc DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 5,866,581 ➤ Sign Up
Mylan Pharms Inc MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 4,444,769 ➤ Sign Up
Mylan Pharms Inc ZONALON doxepin hydrochloride CREAM;TOPICAL 020126-001 Apr 1, 1994 4,395,420 ➤ Sign Up
Mylan Pharms Inc AVITA tretinoin CREAM;TOPICAL 020404-003 Jan 14, 1997 4,971,800 ➤ Sign Up
Mylan Pharms Inc DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 5,075,445 ➤ Sign Up
Mylan Pharms Inc ZOVIRAX acyclovir TABLET;ORAL 020089-001 Apr 30, 1991 4,199,574 ➤ Sign Up
Mylan Pharms Inc DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 5,916,893 ➤ Sign Up
Mylan Pharms Inc DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 5,840,763 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MYLAN PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Foam 2% ➤ Subscribe 7/30/2009
➤ Subscribe Foam 0.12% ➤ Subscribe 8/10/2007
➤ Subscribe Topical Foam 0.05% ➤ Subscribe 6/27/2005

Non-Orange Book US Patents for Mylan Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,075,445 Guanine derivatives ➤ Sign Up
5,684,153 Process for the preparation of purine derivatives ➤ Sign Up
8,263,580 Vitamin formulation ➤ Sign Up
5,886,215 2-acetoxymethyl-4-halo-butyl-1-yl acetates ➤ Sign Up
6,388,074 Process for the preparation of purine derivatives ➤ Sign Up
9,492,384 Microemulsion and sub-micron emulsion process and compositions ➤ Sign Up
8,298,515 Vitamin formulation ➤ Sign Up
6,573,378 Antiviral guanine derivatives ➤ Sign Up
6,187,922 Process for the preparation of purine derivatives ➤ Sign Up
8,449,867 Microemulsion and sub-micron emulsion process and compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Mylan Pharms Inc Drugs

Country Document Number Estimated Expiration
Spain 543213 ➤ Sign Up
Japan H0826021 ➤ Sign Up
Germany 69122229 ➤ Sign Up
China 1053547 ➤ Sign Up
Hungary 9202431 ➤ Sign Up
New Zealand 508259 ➤ Sign Up
Denmark 1112062 ➤ Sign Up
European Patent Office 1024792 ➤ Sign Up
Greece 852272 ➤ Sign Up
Morocco 22051 ➤ Sign Up
Country Document Number Estimated Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Mylan Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
11/016 Ireland ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
C/GB02/046 United Kingdom ➤ Sign Up PRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515
2011 Austria ➤ Sign Up PRODUCT NAME: KOMBINATION AUS OLMESARTAN MEDOXOMIL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH AKZEPTABLEN SALZES, AMLODIPIN BESILAT UND HYDROCHLOROTHIAZID; NAT. REGISTRATION NO/DATE: 1-30068 - 1-30072 20110216; FIRST REGISTRATION: DE 79810.00.00 - 79814.00.00, UND 79815.00.00 - 79819.00.00 20101216
00221 Netherlands ➤ Sign Up PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
1411900/01 Switzerland ➤ Sign Up PRODUCT NAME: ESOMEPRAZOL + NAPROXEN; REGISTRATION NO/DATE: SWISSMEDIC 61330 06.05.2011
00205 Netherlands ➤ Sign Up PRODUCT NAME: RASAGILINE, DESGEWENST IN DE VORM VAN EENFARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/04/304/001 T/M 007 20050221
1273292/01 Switzerland ➤ Sign Up PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC 58751 28.05.2009
/2008 Austria ➤ Sign Up PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
C/GB07/065 United Kingdom ➤ Sign Up PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021
C0005 France ➤ Sign Up PRODUCT NAME: LINEZOLIDE; NAT. REGISTRATION NO/DATE: NL 26 660 20010831; FIRST REGISTRATION: GB - PL 00 32/0261 20010105
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Argus Health
Healthtrust
McKesson
Chinese Patent Office
Cantor Fitzgerald
Merck
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot